Gerresheimer Business Model Canvas

Gerresheimer secures high-purity quartz sand and medical-grade polymers via multi-year supply contracts—cutting input-price volatility and guaranteeing >30% recycled content in select lines by 2025; raw-material spend totaled ~€520m in 2024.

By 2025 Gerresheimer partners with renewable energy providers to source 60–80% of electricity for glass furnaces, supporting its target to halve Scope 1+2 emissions vs.2019 and lowering energy costs amid volatile fuel markets.

Gerresheimer's key partnerships span pharma co-development (committed >€400m volumes by end-2025), tech partners for connected devices (digital sales +12% in 2024), secured raw-material spend ~€520m (2024), and renewable-energy contracts to source 60–80% furnace power by 2025, reducing Scope1+2 emissions ~50% vs 2019.

Maintaining rigorous QC and regulatory compliance is non-negotiable: Gerresheimer follows FDA, EMA and other authorities, supporting >€1.6bn 2024 revenues by preserving market access. The company runs exhaustive extractables/leachables and container-closure integrity testing—reducing batch rejection risk below industry avg 1.5%—and sustains ISO 13485 and GMP certifications required to serve pharma clients.

High-volume, high-precision manufacturing of glass/plastic pharma packaging and drug-delivery devices (≈3.2bn units, €1.4bn manufacturing revenue in 2024), plus R&D (~€100–130m p.a.; 30–40% on GLP‑1 by late 2025) and strict QC/regulatory programs (ISO 13485/GMP; batch rejection <1.5%) supporting global supply, AI-driven demand planning (85% utilization 2024) and consultative B2B sales securing 3–7y contracts.

The workforce includes expert glass blowers, polymer scientists, biomedical engineers and regulatory specialists; this talent base is critical for solving engineering challenges and meeting CE/FDA standards. In 2024 Gerresheimer invested ~€28m in training and R&D staff development, supporting a 6% rise in qualified operators and sustaining a 99.7% batch-release quality rate.

Gerresheimer’s 31 sites, 2024 €2.1bn revenue, €150m net cash and €300–€400m capex plan enable >60% capacity use; patents and Gx Elite glass drove €1.2bn device sales and ~15–25% ASP premium; 45 connected-device filings (2022–25) lift IP margin 8–12% and staff/R&D spend €28m supported 99.7% batch-release quality.

Gerresheimer partners with clients to co-create bespoke packaging—like custom syringes for high-viscosity biologics and luxury-branded glass for cosmetics—boosting device-drug fit and patient usability; 2024 co-development orders grew 18% year-over-year, accounting for ~27% of pharma segment sales (€430m of €1.6bn). This flexibility shortens time-to-market and can cut device-related returns by up to 12% in pilot programs.

Gerresheimer provides high-integrity glass/polymer primary packaging and drug-delivery devices that cut biologic loss, speed approvals, and boost margin—2025 pharma revenue €1.05bn (primary packaging ~62%), device sales €842m (2024), 95% first-time approval rate (2024), co-dev orders €430m (27% pharma sales), sustainability options cut lifecycle CO2 up to 35% and added ~8% revenue uplift (2024–25).

For innovative delivery devices Gerresheimer signs joint development agreements sharing risks and rewards with clients, which in 2025 accounted for roughly 18% of its pharma packaging projects and helped secure exclusive manufacturing rights in ~30% of collaborations; these high-touch, trust-based partnerships are typical in biotech where specialized delivery drives therapy value and can lift contract margins by 200–400 basis points.

Gerresheimer builds long-term, high-touch partnerships via multi-year contracts, key-account teams, joint development deals and digital self-service, driving ~70% recurring sales of €1.7bn (2024), key accounts ~42% (€1.2bn, 2024), services ~6% (€64m, 2024), JDAs ~18% of projects (2025) and retention +6–8% (2024–25).

Gerresheimer uses its corporate website, LinkedIn, and industry portals to publish whitepapers, case studies, and product specs, targeting R&D scientists and procurement officers seeking containment and delivery solutions; digital channels drove 38% of B2B inquiries in 2024. In 2025 the company leverages virtual showrooms and webinars—used in 62% of demo engagements globally—to demonstrate device functionality and shorten sales cycles by an average of 22%.

Channels: direct global sales (Basel, NJ, Shanghai) drive complex B2B deals—2024 pharma revenue €1.2bn (~48% sales), EBITDA ~15%; trade fairs (CPHI, Pharmapack, Luxe Pack) generated ~6% new B2B orders (€45m pipeline); digital (site/LinkedIn) = 38% inquiries; distributors cover ~18% packaging revenue in 60+ countries; innovation centers cut prototype lead time ~60%, raise conversion ~25%.

Manufacturers of off-patent drugs buy cost-effective, high-quality packaging to stay competitive in price-sensitive markets; Gerresheimer supplied roughly 1.2 billion glass vials and syringes in 2024, supporting generics and biosimilar firms with scalable, high-volume production. This segment values production efficiency and supply security—Gerresheimer’s 98% on-time delivery in 2024 and multi-site manufacturing reduce stockout risk for large-volume business models.

Global pharma, biotech/biopharma, generics/biosimilars, luxury cosmetics, and healthcare/IVD buyers drive Gerresheimer’s revenue mix: >60% from large pharma (2024), biologics growth ≈€120–150m incremental vs 2022, ~1.2bn glass units sold (2024), 98% on-time delivery, IVD market USD86.5bn (2024), premium glass CAGR 6.8% (2019–24).

Maintaining leadership in drug delivery, Gerresheimer spends roughly 6–8% of 2024 revenues (≈€60–80m) on R and D and engineering, covering specialist salaries, prototyping, and costly clinical validation of new devices. By 2025 about 18–22% of that R and D budget is earmarked for digital health and smart-device integration, reflecting increased investment in connectivity, sensors, and software validation.

Gerresheimer’s cost base is driven by raw materials (~38% of COGS in 2024), energy (6–9% of manufacturing COGS in 2024), payroll (~28–32% of COGS) and high CAPEX (guidance EUR 350–400m for 2024–25) with FY2024 D&A ~EUR 130m; R&D ≈6–8% of revenues (~€60–80m) and compliance ~3–5% of revenue.

Gerresheimer earns revenue by providing end-to-end contract manufacturing for third-party medical devices, including cleanroom injection molding, automated assembly, and specialized packaging tailored to client specs; contract manufacturing contributed about 18% of group sales, roughly EUR 280m in 2024. The model leverages excess capacity and technical expertise across pharma and medtech, with capacity utilization near 78% and annual contract-manufacturing order intake growing ~7% in 2024.

Gerresheimer’s revenues in 2024 were driven by glass primary packaging (~65%, ≈€1.1bn), plastic drug-delivery devices (~€520m), contract manufacturing (~€280m, ~18%), licensing/IP (~€90m, >60% gross margin) and services (≈12% of €2.1bn), with device growth 8–12% YoY and contract manufacturing utilization ~78%.